Navigation Links
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU-176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new Phase II data presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco. These findings are the first results from a Phase II clinical study evaluating an oral Factor Xa inhibitor in atrial fibrillation patients. DU-176b is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568).

The objective of the multinational study was to assess the safety of four dose regimens of DU-176b in patients with non-valvular atrial fibrillation (AF), as compared to warfarin. While the incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg twice per day), compared with warfarin, the incidence reported in the once-daily DU-176b treatment groups (30 mg or 60 mg once per day) was similar to that in the warfarin-treated patient group. Bleeding events were evaluated using guidelines established by the International Society on Thrombosis and Haemostasis(1), the most sensitive scale of those currently used in clinical studies in cardiovascular disease.

"These results are noteworthy and encouraging because we observed significantly fewer adverse bleeding events in patients receiving one dose of DU-176b per day, versus two doses per day, suggesting with this compound, the most convenient dosing regimens also appear to be safer," said Jeffrey I. Weitz, MD, FACP, FRCP, professor of medicine and biochemistry, McMaster University and director, Henderson Research Centre, Hamilton, Ontario. "These data provide insight into the optimal dosing regimens for Phase III studies of DU-176b."


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Armada Health Care (Armada), ... (GPO), is pleased to announce an agreement with ... host of innovative specialty pharmacy patient program offerings. ... therapy management services to specialty patients via Armada,s ... Aurora will use the OTM platform as ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... Pa. , Aug. 21, 2014   ... ), a specialty biopharmaceutical company, today announced positive ... of collagenase clostridium histolyticum (or CCH) for the ... as cellulite. In the Phase 2a trial, all ... and high (0.84mg)) showed an improvement in the ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... (Nasdaq: DNDN ) today announced that the ... convertible senior notes due January 15, 2016 (the "Notes") ... to purchase an additional $80 million aggregate principal amount ... exercise of the overallotment option, resulted in net proceeds ...
... Hospira, Inc. (NYSE: HSP ), the ... Food and Drug Administration (FDA) approval of Topotecan Injection, ... in the United States. The medication is a generic ... more than $140 million. Hospira,s topotecan is indicated for ...
Cached Medicine Technology:Dendreon Announces Exercise and Closing of Overallotment Option 2Hospira Announces FDA Approval of Topotecan Injection 2
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
(Date:8/21/2014)... One of the emerging trends in the market ... This increases the availability and accessibility of these products to ... Ostomy Care Accessories market to grow at a ... the report, the Global Ostomy Care Accessories market is driven ... the major drivers. The number of procedures is increasing owing ...
(Date:8/21/2014)... Australian scientists say a commercially available ... been used to successfully fight mesothelioma in lab mice. ... new research. Click here to read it now. ... treated mesothelioma cells with the S. aureus ... while simultaneously stimulating a stronger anti-tumor response in healthy ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2
... is a primary long-term complication among premature infants suffering ... risk for pulmonary hypertension and impaired growth, and ... neurological problems. ,A new study finds premature ... with inhaled nitric oxide. ,Researchers from the University ...
... have lasted for less than three months. ,A new ... exercise sheet// handouts, and telephone follow-up calls may help ... ,Researchers from Indiana University developed a self-management program for ... focuses on boosting confidence in order to increase their ...
... a step forward in their search for a cure for ... the spleen appear to develop into insulin producing //pancreatic islet ... with diabetes. ,The latest research is a follow ... advanced type 1 diabetes in mice. The new research focuses ...
... New research shows screening newborns for biochemical genetic disorders ... parents. However, researchers say false-positive screening results may increase ... genetic disorders required a separate test, but now, doctors ... just one sample of blood by using a device ...
... transplanting chimpanzee organs into humans in need of an organ ... survived 20 days. // Since then, doctors have continued to ... cells to treat various diseases, all with varying degrees of ... -- also known as xenotransplantation. ,Dick Beyer ...
... Arthritis is a common health problem worldwide. Both osteoarthritis ... patients. There is no cure for arthritis and no ... new study could help lead doctors towards a drug ... the molecular pathway and an enzyme that play a ...
Cached Medicine News:Health News:Screening Newborns Questioned 2Health News:Animals Can give us a second chance at life 2
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation. Two 25G ...
Medicine Products: